Brief: Orthocell Seeks Trading Halt
28/11/2024 22:26
Nov 29 (Reuters) - Orthocell Ltd OCC.AX :
* SEEKS TRADING HALT PENDING RESULTS OF REGULATORY STUDY
REQUIRED
FOR FDA APPROVAL OF REMPLIR
Further company coverage: OCC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense